Effectivity of alkaline water on the clinical improvement in laryngopharyngeal reflux

Muhammad Rizka Yahya, Rery Budiarti, Dwi Antono, Farokah, Muyassaroh*
Department of Otolaryngology-Head and Neck Surgery, Dr. Kariadi Central Hospital Semarang, Indonesia.

ABSTRACT
Laryngopharyngeal reflux (LPR) is the reflux of gastric acid through the upper oesophageal sphincter causing mucosal damage of the larynx, the gastrointestinal tract, and the upper airway. Alkaline water has the ability to withstand acidic conditions in the body, the formation of carbonic anhydrase, and reepithelization. This study aimed to investigate the effect of alkaline water on the clinical improvement in LPR patients. A randomized control trial with pre-test and post-test control group design on LPR patients aged 18 to 60 y.o. was conducted at the ENT-HS outpatient clinic of Dr Kariadi Central Hospital, Semarang, Central Java, Indonesia. Thirty subjects were recruited and divided into two group with 15 subjects in each group. In the control group, the subjects were given standard therapy and mineral water. In the treatment group, the subjects were given standard therapy and alkaline water. The diagnosis of LPR was made if the reflux scoring index (RSI) was ≥13, and the reflux finding score (RFS) was >7. After two weeks of intervention, the clinical improvements were evaluated by reassessing the RSI score. The data were analyzed using the Shapiro-Wilk test and independent t-test. The results showed that the most common main complaint was throat clearing [11 subjects (37%)]. Based on the RSI score, there were clinical improvements in both the control (p <0.001) and the treatment groups (p <0.001). However, there was no significant difference in the RSI score before and after the intervention in the control (p = 0.058) and the treatment groups (p = 0.322). In conclusion, there is an effect of alkaline water on the clinical improvement of LPR patients. However, there is no significant difference in the clinical improvement between the control and the treatment groups.

Keywords: laryngopharyngeal reflux; alkaline water; clinical improvement;
INTRODUCTION

Laryngopharyngeal reflux (LPR) is the reflux of gastric acid into the larynx, pharynx, trachea, and bronchi. The prevalence of LPR is 15%-20% of the total patients visiting the ENT specialists. LPR occurs due to the high acid level. Alkaline water is currently used to neutralize the acidity because alkaline water with a pH of 8.8 can help to reduce acid reflux. The high pH level will inactivate pepsin, an enzyme involved in protein breakdown and the main cause of lower acidity. Apart from that, alkaline water has also been shown to reduce the acidity of stomach contents.

Alkaline water has been established as fit for consumption and beneficial for the human body. One of its most important benefits is its ability to neutralize acidity in the body by reducing excess acid content in the stomach. Furthermore, alkaline water can boost the immune system, as well as neutralize acidity in the body caused by poor diet, stress, and environmental toxins. Alkaline water can also absorbed by the body, and is rich in alkaline minerals. With the availability of abundance electrons, alkaline water allows the body cells to eliminate the harmful free radicals.

Alkaline water with a pH of 8.8 can help reduce gastric acid reflux because higher pH levels will inactivate pepsin, an enzyme involved in dietary protein breakdown and the main cause of lower acidity. However, study concerning the effect of alkaline water on LPR patients has never been conducted. This study aimed to investigate the effect of alkaline water on the clinical improvement of LPR patients.

MATERIALS AND METHODS

Design and sample size

This was a randomized control trial with a pre-test and post-test control group design, conducted at the ENT-HS outpatient clinic of Dr. Kariadi Central Hospital, Semarang, Central Java. This study had obtained ethical approval from the Health Research Ethics Committee of Dr. Kariadi Central Hospital, Semarang.

The sample size for each group was determined by the calculation formula used in previous studies. With the standard deviation of 4.7, α of 0.05, and power of 90%, the sample size obtained was 13.8, which was then rounded to 14. Then a drop-out count of 10% was added and the final sample size for each group consisted of 15 people.

Protocol of study

The diagnosis of LPR was conducted based on the reflux scoring index (RSI), a complete ENT examination, and reflux finding score (RFS) using flexible laryngoscopy/ fiberoptic laryngoscope (FOL). The diagnosis of LPR was established if the RSI score was ≥13 and the RFS score was >7. The samples were collected using consecutive sampling and single blinding methods.

The inclusion criteria of this study included: 1) patients with LPR (RSI of ≥13; RFS of >7), 2) aged 18-60 years old, and 3) willing to take part in the study. Meanwhile, the exclusion criteria included: 1) patients with head and neck malignancies, 2) patients with acute lower and upper respiratory tract infections (rhinitis, pharyngitis, tonsillitis, or bronchitis), and 3) had a previous history of undergoing radiotherapy in the neck area.

In the control group, 15 subjects were given standard therapy consisting of 20 mg of omeprazole every 12 hours and 1.8 L of mineral water per day for 2 weeks. Meanwhile, in the treatment group, 15 subjects were given 1.8 L of alkaline water per day and 20 mg of omeprazole every 12 h for two weeks. Both of groups
were evaluated after two weeks by reassessing clinical improvement using the RSI score.

**Statistical analysis**

A normality test of the data was performed using the Shapiro-Wilk test, which showed a normal data distribution. Finally, the data were analyzed using the independent t-test or Wilcoxon test or Fischer’s exact test. A p value < 0.05 was considered significant.

**RESULTS**

A total of 30 subjects who met the inclusion and exclusion criteria were randomized into two groups i.e. treatment and control groups.

| TABLE 1. Data distribution |
|-----------------------------|
| Variables                  | Groups | p    |
|                            | Control | Treatment |    |
| Sex                        |         |         |    |
| • Male [n (%)]              | 2 (13.3) | 3 (20)    | 1.000* |
| • Female [n (%)]            | 13 (86.7) | 12 (80)   |      |
| Age (mean ± SD years)       | 43.20 ± 9.76 | 45.60 ± 8.73 | 0.484** |
| Age categories [n (%)]      |         |         |    |
| • 15 – 20                   | 0 (0)    | 0 (0)     |    |
| • >20 – 30                  | 2 (7)    | 1 (3)     |    |
| • >30 – 40                  | 3 (10)   | 4 (13)    |    |
| • >40 – 50                  | 7 (23)   | 6 (20)    |    |
| [n (%)]>50 – 60             | 3 (10)   | 4 (13)    |    |

Notes: *Independent t-test; **Fischer’s exact test.

TABLE 1 shows the characteristics of the subjects based on sex in the two groups, consisting of 5 (16.7%) male and 25 (83.3%) female subjects. The sex distribution in the two groups were homogeneous (p = 1.0). The distribution of subjects based on age show that the highest number of subjects was in the 41-50 years age group, which were 13 (43%) subjects. The age distribution in the two groups were homogeneous (p = 0.484). The mean age in both groups was 43 ± 9.756 years, with an age range of 21-60 years.

| TABLE 2. Distribution of chief complaints |
|------------------------------------------|
| Chief complaints                        | n (%) |
| Hoarseness                              | 4 (13) |
| Throat clearing                         | 11 (37) |
| Mucus in the throat                     | 5 (17) |
| Swallowing difficulty                   | 2 (7) |
| Coughing after eating or lying down     | 1 (3) |
| Breathing difficulty                    | 0 (0) |
| Nagging cough                           | 1 (3) |
| A lump in the throat                    | 6 (0.2) |
| Heart-burn, chest pain, indigestion, gastric acid reflux | 0 (0) |

The most frequent main complaint that brought subjects for treatment was throat clearing [11 patients (37%)], followed by mucus in the throat [5 patients (17%)]. Meanwhile, complaints of heartburn and difficulty in breathing were not the main complaints that brought subjects to come for treatment.
TABLE 3. Pre-test and post-test RSI score results

| Variables       | Groups          | p       |
|-----------------|-----------------|---------|
|                 | Control         | Treatment |       |
| Pre-test        | 22.27 ± 3.26    | 24.47 ± 2.83 | 0.058* |
| Post-test       | 18.27 ± 2.92    | 17.33 ± 2.09 | 0.322* |
| p               | <0.001*         | <0.001*   |         |

Notes: *Independent t-test (significant if the p value was <0.05)

TABLE 3 shows an insignificant decrease in the RSI score (p >0.005) after two weeks of intervention both in the treatment and control groups. The mean pre-test RSI scores in the control and treatment groups were 22.27 ± 3.26 and 24.47 ± 2.83 respectively. Meanwhile, the mean post-test RSI scores in the treatment and control groups were 18.27 ± 2.92 and 17.33 ± 2.09, respectively. The results of statistical tests showed no significant differences (p >0.05) in the mean RSI score before and after the intervention both in the treatment and control groups.

TABLE 4. Pre-test and post-test RSI score analysis in the treatment and control groups

| RSI                          | Groups          |
|------------------------------|-----------------|
|                              | Control         | Treatment     |
| Hoarseness                   | 0.008           | <0.001        |
| Throat clearing              | 0.004           | <0.001        |
| Mucus in the throat          | 0.002           | 0.001         |
| Swallowing difficulty        | 0.414           | 0.034         |
| Coughing after eating or lying down | 0.020        | 0.021         |
| Breathing difficulty         | 0.157           | 0.109         |
| Nagging cough                | 0.020           | 0.001         |
| A lump in the throat         | 0.008           | 0.001         |
| Heartburn, chest pain, indigestion, gastric acid reflux | 0.248 | 0.013         |

Notes: *Wilcoxon test; ¤Significant

Based on the statistical analysis (TABLE 4), we found a significant improvement in RSI score of the control group, in exception to swallowing difficulty, breathing difficulty, heartburn, chest pain, indigestion, and gastric acid reflux complaints. Meanwhile, in the treatment group, we found improvements in almost all complaints, except for breathing difficulty.

DISCUSSION

This study involved 30 LPR patients, with a mean age of 43 ± 9.756 y.o (range 21 to 60 years). The highest number of subjects was found in the 51 to 60 years age group (23%). This result was different from previous studies, where LPR was mostly found in the 41-50 age groups (43%). Other studies showed that LPR cases were mostly found in subjects aged over 60 years. The results of this study indicated that LPR cases were more frequently found in female subjects (83.3%) compared to male subjects (16.7%), with a ratio of 1.7:1.9,10

The most frequent main complaint that brought subjects for treatment was throat clearing [11 patients (37%)]. Meanwhile, complaints of heartburn and difficulty in breathing were not the main complaints that brought subjects to come for treatment.

RSI scoring measurement analysis

No significant difference in mean pre-test and post-test RSI scores between the treatment and the control groups.
(p<0.05) was observed. This result might be caused by the gastric feedback mechanism to detect an increased pH, thus signalling the gastric wall to produce more chloric acid to return normal gastric acidity (pH of 4), and causing lesions on the laryngeal mucosa. All of these conditions eventually affect the RSI score measurement.  

Idit was found that the RSI scores increased in almost all complaints in the treatment group compared to the RSI scores in the control group (TABLE 4). These improvements include improvement in symptoms of hoarseness, throat clearing, mucus in the throat, swallowing difficulty, coughing after eating or lying down, nagging cough, a lump in the throat, heartburn, chest pain, indigestion, and gastric acid reflux. Meanwhile, in the control group, there were only a few improvements in several complaints, such as hoarseness, clearing throat, mucus in the throat, nagging cough, and a lump in the throat. These results might be caused of the omeprazole given to each subject in both groups. Omeprazole was believed to reduce the complaints, given its function as a proton-pump inhibitor (PPI) agent. This statement was proved by subjects in the treatment group, who received omeprazole-alkaline water regimen, experienced more improvements compared to subjects in the control group. These symptoms may be caused by high hydrogen content in alkaline water acting as an anti-oxidant to reduce the reactive oxygen species (ROS) levels in the body. ROS is a very reactive molecule formed primarily in the electron transport chain in mitochondria. ROS plays an important role in the normal physiological process, such as regulation of protein phosphorylation redox, ion channel, and transcription process. Excessive production of ROS would cause cell and tissue damage leading to an urgent need for an anti-oxidant to neutralize the ROS. Alkaline water with pH of 8.8 may help reducing acid reflux because higher pH level will inhibit pepsin, an enzyme involved in dietary protein breakdown and the main cause of decreased acidity.

CONCLUSION

There are clinical improvements both in the control and treatment groups. However, the clinical improvements are not significantly different between subjects given either alkaline water or mineral water. Future studies are needed with a consideration of the duration of therapy based on the LPR management guidelines to improve the clinical improvements.

ACKNOWLEDGEMENT

We would like to express our gratitude to all the members of the Department of Otolaryngology-Head and Neck Surgery, Dr. Kariadi Central Hospital, Semarang, Indonesia for the full supports throughout the writing process of this report.

REFERENCES

1. Lechien JR, Akst LM, Hamdan AL, Schindler A, Karkos PD, Barillari MR, et al. Evaluation and management of laryngopharyngeal reflux disease: state of the art review. Otolaryngol - Head Neck Surg (United States) 2019; 160(5):762-782. https://doi.org/10.1177/0194599819827488
2. Zalvan CH, Hu S, Greenberg B, Geliebter J. A comparison of alkaline water and mediterranean diet vs proton pump inhibition for treatment of laryngopharyngeal reflux. JAMA Otolaryngol - Head Neck Surg 2017; 143(10):1023-1029. https://doi.org/10.1001/jamaoto.2017.1454
3. Weinsheim T, Lesser H, Sataloff RT. Unforeseen consequence of alkaline
water therapy for laryngopharyngeal reflux. Ear Nose Throat J 2018; 97(12):394-395.

4. Campagnolo AM, Priston J, Thoen RH, Medeiros T, Assunção AR. Laryngopharyngeal reflux: diagnosis, treatment, and latest research. Int Arch Otorhinolaryngol 2014; 18(2):184-191. https://doi.org/10.1055/s-0033-1352504

5. Khushboo P, Lipsa S, Priti Y, Divya P, Kaenat S, Shivani P. Alkaline water: the disease fighting water. World J Pharm Res 2014; 3(3):3845-3853.

6. Ignacio RMC, Joo KB, Lee KJ. Clinical effect and mechanism of alkaline reduced water. J Food Drug Anal 2012; 20(1 Suppl):394-397. https://doi.org/10.38212/2224-6614.2099

7. Henry M, Chambron J. Physico-chemical, biological and therapeutic characteristics of electrolyzed reduced alkaline water (ERAW). Water (Switzerland) 2013; 5(4):2094-2115. https://doi.org/10.3390/w5042094

8. Koufman JA, Johnston N. Potential benefits of pH 8.8 alkaline drinking water as an adjunct in the treatment of reflux disease. Ann Otol Rhinol Laryngol 2012; 121(7):431-434. https://doi.org/10.1177/000348941212100702

9. Andriani Y, Akil MA, Gaffar M, Punagi AQ. Deteksi pepsin pada penderita refluks laringofaring yang didiagnosis berdasarkan reflux symptom index dan reflux finding score. Oto Rhino Laryngol Indones 2011; 41(2):121. https://doi.org/10.32637/orli.v41i2.48

10. Kamani T, Penney S, Mitra I, Pothula V. The prevalence of laryngopharyngeal reflux in the English population. Eur Arch Oto Rhino-Laryngology 2012; 269(10):2219-2225. https://doi.org/10.1007/s00405-012-2028-1

11. Koufman JA. Low-acid diet for recalcitrant laryngopharyngeal reflux: Therapeutic benefits and their implications. Ann Otol Rhinol Laryngol 2011; 120(5):281-287. https://doi.org/10.1177/00034894112000501

12. Phan J, Benhammou JN, Pisegna JR. Gastric hHypersecretory sStates: iInvestigation and mManagement. Curr Treat Options Gastroenterol 2015; 13(4):386-397. https://doi.org/10.1007/s11938-015-0065-8

13. Kinoshita Y, Ishimura N, Ishihara S. Advantages and dDisadvantages of lLong-term pProton pPump iInhibitor uUse. J Neurogastroenterol Motil 2018; 24(2):182-196. https://doi.org/10.5056/jnm18001

14. Liu X, Jiang Y, Luo H, Liu H. Proton pump inhibitors for the treatment of laryngopharyngeal reflux disease: A protocol for systematic review and meta-analysis. Medicine (Baltimore) 2020; 99(49):e23297. https://doi.org/10.1097/MD.0000000000023297

15. Tanaka Y, Saihara Y, Izumotani K, Nakamura H. Daily ingestion of alkaline electrolyzed water containing hydrogen influences human health, including gastrointestinal symptoms. Med Gas Res 2019; 8(4):160-166. https://doi.org/10.4103/2045-9912.248267